AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36922827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (aerobic exercises, resistance exercises, breathing exercises, psychological improvement strategies, nutritional supplementation)
Number of subjects: 100
Study 36922827 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training-only program
Number of subjects: 100
Study 36922827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Number of subjects: 100
Study 36922864 — intervention group
Group type: EXPERIMENTAL
Intervention: Achondroplasia patients
Number of subjects: 186
Study 36922871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, interactive online risk-reduction behavioural intervention
Number of subjects: 246
Study 36922871 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated home-based HCV-RNA self-sampling test service using dried blood spots
Number of subjects: 246
Study 36922871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both interventions (online risk-reduction intervention and HCV-RNA self-sampling)
Number of subjects: 246
Study 36922871 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 246
Study 36922871 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (online questionnaire measuring risk behaviour)
Number of subjects: 246
Study 36922936 — intervention group
Group type: EXPERIMENTAL
Intervention: ZL-1211 (anti-CLDN18.2 therapeutic antibody)
Number of subjects: 0
Study 36922962 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based intervention for procrastination; details on dosage and duration not available.
Number of subjects: 0
Study 36922962 — intervention group
Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study 36923108 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 412
Study 36923108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart one to three times daily
Number of subjects: 412
Study 36923108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart three times daily with insulin detemir once daily
Number of subjects: 412
Study 36923108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir once daily
Number of subjects: 412
Study 36923108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 36923305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavorixafor monotherapy
Number of subjects: 16
Study 36923305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavorixafor in combination with pembrolizumab
Number of subjects: 16
Study 36923307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610) 225 mg tablet daily
Number of subjects: 64
Study 36923307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)
Number of subjects: 64
Study 36923433 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models (random forest, gradient boosting decision tree, extreme gradient boosting, logistic regression)
Number of subjects: 1152
Study 36923433 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 1152
Study 36923433 — intervention group
Group type: COMPARATOR
Intervention: Multivariable logistic regression model
Number of subjects: 1152
Study 36923454 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan (0.3 mg/kg daily subcutaneous)
Number of subjects: 27
Study 36923454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 36923454 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Number of subjects: 27
Study 36923556 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-676
Number of subjects: 0
Study 36923571 — intervention group
Group type: COMPARATOR
Intervention: AV-101 (1 mg, 3 mg, 10 mg, 30 mg, 90 mg)
Number of subjects: 82
Study 36923571 — intervention group
Group type: COMPARATOR
Intervention: AV-101 (10 mg, 30 mg, 90 mg)
Number of subjects: 82
Study 36923571 — intervention group
Group type: COMPARATOR
Intervention: Oral imatinib (400 mg)
Number of subjects: 82
Study 36923684 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA)
Number of subjects: 94
Study 36924196 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 4
Study 36924249 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet therapy
Number of subjects: 0
Study 36924288 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36924413 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS to the Left Dorsolateral Prefrontal Cortex (DLPF)
Number of subjects: 31
Study 36924413 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study 36924606 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 21
Study 36924606 — intervention group
Group type: EXPERIMENTAL
Intervention: incremental shuttle walk test (ISWT)
Number of subjects: 21
Study 36924606 — intervention group
Group type: EXPERIMENTAL
Intervention: quadriceps isometric muscle strength
Number of subjects: 21
Study 36924606 — intervention group
Group type: COMPARATOR
Intervention: body composition
Number of subjects: 21
Study 36924778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 2205
Study 36924778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 2205
Study 36924778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2205
Study 36924936 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet (12 SQ-HDM dose)
Number of subjects: 253
Study 36925072 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal preconception hemoglobin (Hb)
Number of subjects: 5000
Study 36925072 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal preconception anemia
Number of subjects: 5000
Study 36925074 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal and Intensity Modulated Radiation
Number of subjects: 0
Study 36925176 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg taken once per day for 3 days)
Number of subjects: 1583
Study 36925176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g taken three times per day for 5 days)
Number of subjects: 1583
Study 36925176 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no immediate antibiotics)
Number of subjects: 1583
Study 36925176 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (standard of care, azithromycin, amoxicillin)
Number of subjects: 1583
Study 36925177 — intervention group
Group type: EXPERIMENTAL
Intervention: Community delivery of IPTp (C-IPTp)
Number of subjects: 18215
Study 36925644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidutolimod and Atezolizumab (Part A)
Number of subjects: 29
Study 36925644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidutolimod, Atezolizumab, and Radiation Therapy (Part B)
Number of subjects: 29
Study 36925786 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristics (HRC) monitoring
Number of subjects: 3003
Study 36925849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal decolonization intervention
Number of subjects: 3
Study 36925901 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies (34 discrete strategies used from ERIC taxonomy)
Number of subjects: 0
Study 36925901 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal Implementation Strategies Tracking System (LISTS)
Number of subjects: 0
Study 36926933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with primary ventricular fibrillation (VF)
Number of subjects: 953
Study 36926933 — intervention group
Group type: COMPARATOR
Intervention: Controls without VF
Number of subjects: 953
Study 36926939 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP10
Number of subjects: 2219
Study 36926939 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 2219
Study 36926939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both biomarkers combined
Number of subjects: 2219
Study 36926939 — intervention group
Group type: COMPARATOR
Intervention: BMP10 in low NT-proBNP category
Number of subjects: 2219
Study 36926939 — intervention group
Group type: COMPARATOR
Intervention: BMP10 in high NT-proBNP category
Number of subjects: 2219
Study 36927054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop
Number of subjects: 0
Study 36927054 — intervention group
Group type: COMPARATOR
Intervention: Sensor-Augmented Pump Therapy
Number of subjects: 0
Study 36927114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 36927114 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36927115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100
Study 36927115 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 100
Study 36927115 — intervention group
Group type: COMPARATOR
Intervention: Propensity score matching
Number of subjects: 100
Study 36927115 — intervention group
Group type: COMPARATOR
Intervention: Simulations
Number of subjects: 100
Study 36927237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) group, instructed remotely
Number of subjects: 31
Study 36927237 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), instructed in the clinic
Number of subjects: 31
Study 36927295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 224766
Study 36927339 — intervention group
Group type: EXPERIMENTAL
Intervention: Back At work After Surgery (BAAS) clinical pathway
Number of subjects: 0
Study 36927339 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36927366 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab treatment for 3 months
Number of subjects: 65
Study 36927409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar traction therapy (30 min a day, continuous mode with a force level of 25-30% of body weight) in normal-weight group
Number of subjects: 28
Study 36927409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar traction therapy (30 min a day, continuous mode with a force level of 25-30% of body weight) in obesity group
Number of subjects: 28
Study 36927409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 36927419 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT-guided biopsy
Number of subjects: 200
Study 36927419 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT-guided biopsy
Number of subjects: 200
Study 36927420 — intervention group
Group type: EXPERIMENTAL
Intervention: Canocapavir 50 mg
Number of subjects: 30
Study 36927420 — intervention group
Group type: EXPERIMENTAL
Intervention: Canocapavir 100 mg
Number of subjects: 30
Study 36927420 — intervention group
Group type: EXPERIMENTAL
Intervention: Canocapavir 200 mg
Number of subjects: 30
Study 36927420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36927455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Interferon beta-1a (IFN β-1a)
Number of subjects: 296
Study 36927455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 36927458 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G hybrid closed-loop (HCL) insulin delivery system
Number of subjects: 92
Study 36927458 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) - continuation of current T1D treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) and any type of CGM
Number of subjects: 92
Study 36927459 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic/video CBT-CP program (8 sessions)
Number of subjects: 0
Study 36927459 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT-CP-based program (painTRAINER, 8 sessions)
Number of subjects: 0
Study 36927459 — intervention group
Group type: COMPARATOR
Intervention: Usual care with written guide for chronic pain management
Number of subjects: 0
Study 36927459 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Telephonic/video CBT-CP, Online CBT-CP, Usual care)
Number of subjects: 0
Study 36927462 — intervention group
Group type: EXPERIMENTAL
Intervention: UMGI capsule endoscopy
Number of subjects: 30
Study 36927460 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMA intervention (simulation team-training curriculum for labor and delivery providers)
Number of subjects: 206
Study 36927461 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS-C (combined Adapted and Standard)
Number of subjects: 576
Study 36927461 — intervention group
Group type: COMPARATOR
Intervention: Adapted TranS-C
Number of subjects: 576
Study 36927461 — intervention group
Group type: COMPARATOR
Intervention: Adapted versus Standard TranS-C
Number of subjects: 576
Study 36927496 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled blood pressure monitoring with teleconsultation
Number of subjects: 21
Study 36927496 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of the intervention equipment and management portal
Number of subjects: 21
Study 36927496 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder feedback on sociotechnical aspects of the technology
Number of subjects: 21
Study 36927500 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures (SS/CF) intervention
Number of subjects: 674
Study 36927500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 674
Study 36927527 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3174998 (0.003-10 mg/kg)
Number of subjects: 138
Study 36927527 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3174998 (0.3 mg/kg)
Number of subjects: 138
Study 36927527 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3174998 (P1)
Number of subjects: 138
Study 36927527 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (P2)
Number of subjects: 138
Study 36927527 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3174998±pembrolizumab
Number of subjects: 138
Study 36927585 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin (CAPOX) chemotherapy, tislelizumab, and preoperative split-course hypofraction radiotherapy (SCHR) (5×7 Gy)
Number of subjects: 50
Study 36927591 — intervention group
Group type: EXPERIMENTAL
Intervention: Simply B electronic hepatitis B support package
Number of subjects: 0
Study 36927591 — intervention group
Group type: COMPARATOR
Intervention: Control group (before implementation)
Number of subjects: 0
Study 36927591 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 months after implementation)
Number of subjects: 0
Study 36927591 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 months after implementation)
Number of subjects: 0
Study 36927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) measured on 12 different locations on the lower back using a manual algometer.
Number of subjects: 82
Study 36927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale to record pain intensity and pain affect.
Number of subjects: 82
Study 36927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Index to record associated disability.
Number of subjects: 82
Study 36927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models developed using demographic factors and PPT scores.
Number of subjects: 82
Study 36927597 — intervention group
Group type: EXPERIMENTAL
Intervention: Online multimodal intervention delivered by trained hospital volunteers over 3 months
Number of subjects: 30
Study 36927680 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 890
Study 36927680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 890
Study 36927754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise and exposure to air pollution (specific dosage and duration not mentioned)
Number of subjects: 90
Study 36927754 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study 36927811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelactation-delivered antenatal milk expression (AME) education intervention
Number of subjects: 280
Study 36927811 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 280
Study 36927812 — intervention group
Group type: EXPERIMENTAL
Intervention: XGB model
Number of subjects: 6578
Study 36927812 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 6578
Study 36927812 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model
Number of subjects: 6578
Study 36927812 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine model
Number of subjects: 6578
Study 36927812 — intervention group
Group type: COMPARATOR
Intervention: US guidelines and clinical diagnosis
Number of subjects: 6578
Study 36927882 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation of the Anterior Nucleus of the Thalamus (ANT DBS)
Number of subjects: 191
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk Neutrophil-to-Lymphocyte Ratio (NLR)
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk Gustave Roussy Immune Score (GRIm-S)
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk Memorial Sloan Kettering Prognostic Score (MPS)
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk GRIm-S
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG ≥ 1
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-like subtype
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-HRDetect
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk MPS
Number of subjects: 263
Study 36927977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk GRIm-S
Number of subjects: 263
Study 36928064 — intervention group
Group type: EXPERIMENTAL
Intervention: Heteroscedastic model
Number of subjects: 2288
Study 36928064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantile model
Number of subjects: 2288
Study 36928064 — intervention group
Group type: COMPARATOR
Intervention: Gardosi model
Number of subjects: 2288
Study 36928064 — intervention group
Group type: EXPERIMENTAL
Intervention: All three models (Heteroscedastic, Quantile, Gardosi)
Number of subjects: 2288
Study 36928072 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based cohort study
Number of subjects: 0
Study 36928072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Cox's proportional hazards model
Number of subjects: 0
Study 36928072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable models with propensity score adjustment
Number of subjects: 0
Study 36928094 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-averaging intervals of 10, 20, and 30 seconds; rolling average intervals of 3 and 7 breaths
Number of subjects: 21
Study 36928190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours in subjects with NAFL
Number of subjects: 40
Study 36928190 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with the highest fasting DNL (75th percentile)
Number of subjects: 40
Study 36928190 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with NAFL but undetectable fasting DNL (25th percentile)
Number of subjects: 40
Study 36928238 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic group cognitive-behavioural therapy (TD-CBT) plus treatment as usual (TAU)
Number of subjects: 0
Study 36928238 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) plus treatment as usual (TAU)
Number of subjects: 0
Study 36928238 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICURs)
Number of subjects: 0
Study 36928238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms, quality of life (QoL), functioning, and treatment satisfaction
Number of subjects: 0
Study 36928238 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance and group satisfaction
Number of subjects: 0
Study 36928290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, cyclophosphamide, and dexamethasone
Number of subjects: 0
Study 36928313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single-shot ESPB with a local anesthetic mixture of 10 mL 0.5% bupivacaine, 5 mL 2% lidocaine, and 5 mL saline
Number of subjects: 60
Study 36928313 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 60
Study 36928313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral single-shot ESPB
Number of subjects: 60
Study 36928350 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD-H (allowing limited vertical opening)
Number of subjects: 31
Study 36928350 — intervention group
Group type: COMPARATOR
Intervention: MAD-S (allowing free vertical opening)
Number of subjects: 31
Study 36928395 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells (alloBM-MSCs) infusion
Number of subjects: 19
Study 36928527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously on day 1) added to ICE chemotherapy (ifosfamide, carboplatin, etoposide) every 21 days for 2 cycles, followed by 1 cycle of pembrolizumab monotherapy.
Number of subjects: 42
Study 36928584 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with lenvatinib and GEMOX (gemcitabine plus oxaliplatin)
Number of subjects: 30
Study 36928627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 152
Study 36928627 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 152
Study 36928705 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 0
Study 36928705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36928818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + chemotherapy (Nivo+CT)
Number of subjects: 44